SCHEMBL31359005

SCHEMBL31359005

O=C(Cn1c(=O)[nH]c2ccccc2c1=O)NCc1ccccn1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.57
KAT2A Q92830 1/20 0.57
KAT2B Q92831 1/20 0.57
KDM4E B2RXH2 6/20 0.56
ALDH1A1 P00352 3/20 0.56
GAA P10253 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
GLA P06280 1/20 0.56
HTT P42858 1/20 0.56
HSD17B10 Q99714 3/20 0.55
HPGD P15428 1/20 0.55
NTRK1 P04629 4/20 0.51
NTRK3 Q16288 2/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
F2 P00734 1/20 0.50
MAPK10 P53779 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24480194 0.84 KDM4E (0.57) POLBKDM4EALDH1A1GAASMN1; SMN2
SCHEMBL31359093 0.82 ALDH1A1 (0.61) POLBKDM4EALDH1A1GAAGLA
SCHEMBL6982033 0.79 ALDH1A1 (0.64) POLBKDM4EALDH1A1GAASMN1; SMN2
SCHEMBL15752150 0.79 RECQL (0.64) POLBKAT2AKAT2BKDM4EALDH1A1
SCHEMBL31359141 0.77 MAPT (0.53) POLBKDM4EALDH1A1SMN1; SMN2HSD17B10
SCHEMBL31359042 0.75 KMT2A (0.51) POLBKDM4EALDH1A1HSD17B10HPGD
SCHEMBL31359092 0.75 GCK (0.50) POLBKDM4EALDH1A1GAASMN1; SMN2
SCHEMBL3311524 0.73 ALDH1A1 (0.73) KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD
SCHEMBL11985495 0.72 CYP1A2 (0.67) KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD
SCHEMBL31359100 0.72 KMT2A (0.60) POLBKDM4EALDH1A1SMN1; SMN2GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559464-B2 Quinazolinone dione compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2026-02-24 US disclosed
US-20250026726-A1 QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026726-A1 QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, MYLK2 POLB 3950/4885KAT2A 2734/4885KAT2B 3260/4885
US-12559464-B2 Quinazolinone dione compounds and uses thereof TNNI3, TNNT2, TNNC1 POLB 2280/4885KAT2A 2125/4885KAT2B 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.